

Resource Summary Report

Generated by [dkNET](#) on Sep 11, 2026

KM-H2

RRID:CVCL_1330

Type: Cell Line

Proper Citation

RRID:CVCL_1330

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1330

Proper Citation: RRID:CVCL_1330

Description: Cell line KM-H2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Hodgkin lymphoma

Defining Citation: [PMID:2602653](#), [PMID:2690233](#), [PMID:3013343](#), [PMID:3359046](#), [PMID:8547074](#), [PMID:8558920](#), [PMID:11372738](#), [PMID:17065008](#), [PMID:18194364](#), [PMID:19380639](#), [PMID:20164919](#), [PMID:20628145](#), [PMID:21368758](#), [PMID:22460905](#), [PMID:25355872](#), [PMID:25894527](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29533902](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KM-H2

Synonyms: KM H-2, KMH2

Cross References: BTO:BTO_0004972, CLO:CLO_0007112, CLDB:cl3033, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03473401, BioSample:SAMN10988578, cancercellines:CVCL_1330,

Cell_Model_Passport:SIDM01018, ChEMBL-Cells:CHEMBL3308204, ChEMBL-Targets:CHEMBL2366250, Cosmic:909976, Cosmic:988704, Cosmic:1013910, Cosmic:1086357, Cosmic:1191707, Cosmic:1289700, Cosmic:1290219, Cosmic:1432041, Cosmic:2276325, Cosmic:2361388, Cosmic:2464308, Cosmic-CLP:909976, DepMap:ACH-000815, DSMZ:ACC-8, DSMZCellDive:ACC-8, EGA:EGAS00001000978, GDSC:909976, GEO:GSM335391, GEO:GSM499723, GEO:GSM499731, GEO:GSM552446, GEO:GSM637987, GEO:GSM646533, GEO:GSM887214, GEO:GSM888288, GEO:GSM1669990, IARC_TP53:21433, IARC_TP53:23616, IPD-IMGT/HLA:15116, LiGeA:CCLE_432, LINCS_LDP:LCL-2009, Lonza:21, Pharmacodb:KMH2_752_2019, PRIDE:PXD000589, PRIDE:PXD030304, Progenetix:CVCL_1330, PubChem_Cell_line:CVCL_1330, Wikidata:Q54900048

ID: CVCL_1330

Record Creation Time: 20220427T220704+0000

Record Last Update: 20260905T180941+0000

Ratings and Alerts

No rating or validation information has been found for KM-H2.

No alerts have been found for KM-H2.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Shen Y, et al. (2025) Bispecific Nanosystems Enable Multieffector Immune Cell Retargeting for Hematologic Malignancy Therapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e09103.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. Cell reports. Medicine, 2(7), 100350.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer cell, 39(8), 1115.

Bankov K, et al. (2019) Fibroblasts in Nodular Sclerosing Classical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury. Cancers, 11(11).